MarketFriction

Innova Captab Ltd

NSE INNOVACAP · BSE 544067 · Pharmaceuticals
₹1,168.00 +0.71%
NSE close2026-10-01
52 week range622.00 - 1,353.50
Market cap₹7,274 Cr.
P/E47.2
IPO 2023 · +161% since Price band 20% Delivery 39.9%

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Consolidated, Rs crore
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales283302263294318316315352380450448471
Expenses242258225252268270267299329381383398
Operating Profit404538425047485252696573
OPM %14%15%14%14%16%15%15%15%14%15%15%16%
Other Income326224344222
Interest971000236454
Depreciation553555101111111112
Profit before tax303540394746394339565159
Tax %24%29%27%25%25%25%25%27%24%24%25%25%
Net Profit232529293534303130423844
EPS in Rs4.774.395.025.156.125.985.175.425.187.376.657.71
Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales3563734118019261,0811,2441,6301,749
Expenses3153223567048139271,0571,3871,490
Operating Profit41515496114154186243259
OPM %11%14%13%12%12%14%15%15%15%
Other Income01139121279
Interest6546202121718
Depreciation1110681116254546
Profit before tax2538468692130171188205
Tax %20%26%26%25%26%27%25%25%
Net Profit202834646894128141154
EPS in Rs165.67232.42287.50532.9214.1616.4922.4124.6326.91
Dividend Payout %0%0%0%0%0%0%0%8%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth%32%21%34%
Compounded Profit Growth%32%28%19%
Stock Price CAGR%%%49%
Return on Equity%17%15%14%
Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital1212121248575757
Reserves70981331972297749021,034
Borrowings725446199237245338344
Other Liabilities6881179167191240271401
Total Liabilities2232453705757041,3161,5681,836
Fixed Assets787379183183358830842
CWIP0070223412316
Investments000000041
Other Assets144172283392500617716938
Total Assets2232453705757041,3161,5681,836
Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity193142596714664117
Cash from Investing Activity-9-6-20-188-91-499-152-107
Cash from Financing Activity-9-23-191252736192-22
Net Cash Flow113-5384-12
Free Cash Flow112723-21-11-141-10855
CFO/OP68%79%101%83%76%113%47%59%
Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days938512397104979798
Inventory Days5084107767791119125
Days Payable809213286105113115141
Cash Conversion Cycle64779987777510182
Working Capital Days3045393758778186
ROCE %26%28%31%24%19%15%15%
Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters50.90%50.90%50.90%50.90%50.90%50.90%50.90%50.90%50.90%50.90%50.90%
FIIs3.57%1.94%1.19%1.01%0.74%0.35%0.23%0.08%0.10%0.23%0.34%
DIIs10.31%20.78%21.24%20.61%19.96%19.77%19.67%20.17%20.24%20.14%19.92%
Public35.22%26.39%26.67%27.48%28.41%29.00%29.20%28.86%28.76%28.74%28.84%
No. of Shareholders1,39,11739,39635,11532,25436,69239,99641,01440,24538,69136,96535,881

Fundamentals

Market Cap₹ 7,274 Cr.
Current Price₹ 1,271
Stock P/E47.2
Book Value₹ 191
ROCE15.0 %
ROE13.7 %
Dividend Yield0.16 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)34%
Compounded Profit Growth (TTM)19%
Consolidated figures.
Valuation
Market capRs 6,684 Cr
Enterprise valueRs 6,842 Cr
P/E (TTM)43.39x
Price to book8.04x
Price to sales3.82x
EV / EBITDA25.45x
EV / EBIT30.68x
EV / sales3.91x
Price to cash flow45.67x
Earnings yield2.30%
P/E, 3-year average27.27x
P/B, 3-year average3.10x
P/E, 5-year average27.27x
P/B, 5-year average3.10x
Profitability
Operating margin (excl. other income)14.28%
Operating margin (incl. other income)15.44%
EBITDA margin15.37%
Pre-tax margin11.69%
Net profit margin8.81%
Net margin, latest quarter9.37%
ROE17.04%
ROCE19.00%
ROA9.34%
ROE, 3-year average27.08%
ROCE, 3-year average24.61%
ROA, 3-year average11.17%
ROE, 5-year average27.44%
ROCE, 5-year average25.72%
ROA, 5-year average11.33%
ROIC (approx.)16.42%
Tax rate27.16%
Other income / net worth1.50%
Growth
Sales growth (latest year)16.72%
Profit growth (latest year)38.85%
Sales CAGR, 3 years38.09%
Sales CAGR, 5 years24.90%
Profit CAGR, 3 years39.84%
Profit CAGR, 5 years36.54%
Sales growth QoQ5.15%
Profit growth QoQ15.89%
Sales growth YoY (latest quarter)33.94%
Profit growth YoY (latest quarter)42.26%
Per share
EPS (TTM)Rs 26.92
EPS (latest year)Rs 16.49
EPS (latest quarter)Rs 7.71
EPS, 3-year averageRs 187.85
EPS, 5-year averageRs 216.70
Book value per shareRs 145.20
Sales per shareRs 305.69
Cash flow per shareRs 25.57
Free cash flow per shareRs 9.61
Efficiency
Asset turnover0.82x
Fixed asset turnover3.02x
Inventory turnover5.45x
Inventory days67 days
Debtor days97 days
Debtors turnover3.75x
Creditor days141 days
Cash conversion cycle82 days
Working capital days86 days
Leverage
Total debtRs 245 Cr
Cash and bankRs 87 Cr
Net debtRs 158 Cr
Debt to equity0.29x
Net debt / EBITDA0.59x
Interest coverage12.08x
Current ratio (filing 2026-03-31)1.87x
Quick ratio (filing 2026-03-31)1.29x
Trade payables (filing 2026-03-31)Rs 300 Cr
Owners' fund to total sources63.14%
Debt to assets18.62%
Cash flow
Cash from Operating Activity (latest year)Rs 146 Cr
Cash from Investing Activity (latest year)Rs -499 Cr
Cash from Financing Activity (latest year)Rs 361 Cr
Net Cash Flow (latest year)Rs 8 Cr
Free cash flow (latest year)Rs 55 Cr
FCFE (approx.: FCF + change in debt)Rs 63 Cr
Cash from ops / profit, 5 years0.92x
Sales to cash flow7.39x
Statement figures
Net sales (TTM)Rs 1,749 Cr
Net sales (latest year)Rs 1,081 Cr
Sales (latest quarter)Rs 471 Cr
Operating profit excl. other income (latest year)Rs 154 Cr
Operating profit (latest quarter)Rs 73 Cr
Other income (TTM)Rs 9 Cr
EBITDA (TTM)Rs 269 Cr
PBDT (TTM)Rs 250 Cr
Profit before tax (TTM)Rs 205 Cr
Tax (latest year)Rs 35 Cr
Net profit (TTM)Rs 154 Cr
Net profit (latest year)Rs 94 Cr
Net profit (latest quarter)Rs 44 Cr
Depreciation (TTM)Rs 46 Cr
Depreciation (latest quarter)Rs 12 Cr
Interest (TTM)Rs 18 Cr
Cost of goods sold (latest year)Rs 786 Cr
Total expenditure (latest year)Rs 927 Cr
Total income (latest year)Rs 1,094 Cr
Share capitalRs 57 Cr
ReservesRs 774 Cr
Shareholders' fundsRs 831 Cr
Total assetsRs 1,316 Cr
Net blockRs 358 Cr
Capital work in progressRs 341 Cr
ReceivablesRs 288 Cr
InventoryRs 144 Cr
Other liabilitiesRs 240 Cr
Shares outstanding (crore)5.72
Ownership
Promoter holding50.90% (+0.00 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
P/E 43.4 is at the 57th percentile of its own 2.9-year range (median 40.0, low 28.9, high 99.8).
P/B 8.04 is at the 11th percentile (median 17.77).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
PeriodINNOVACAPNifty 50Difference
1 week-9.8%-2.8% -7.0 pts
1 month+9.4%-6.8% +16.1 pts
3 months+21.9%-7.6% +29.6 pts
6 months+69.3%+0.4% +68.9 pts
1 year+39.1%-9.9% +49.0 pts
2 years+51.9%-13.6% +65.4 pts
13 mutual fund schemes hold about ₹543 Cr. Over three months 1 bought more and 12 sold (share counts, price move removed).
FundWeightEst. Cr3m shares
Canara Rob Small Cap Fund1.20%176 -14%
Kotak Multi Cap Fund0.59%174 -22%
Invesco India Smallcap Fund0.43%68 -23%
Canara Rob Manufacturing Fund1.67%29 -13%
Bandhan Small Cap Fund0.08%26 -31%
Kotak Consumption Fund1.35%23 -12%
Canara Rob Value Fund1.37%18 -12%
Invesco India Manufacturing Fund1.14%8 -17%
TRUSTMF Multi Cap Fund0.97%8 +13%
Kotak Healthcare Fund1.08%7 -20%
WOC Pharma and Healthcare Fund0.60%5 -56%
Bandhan BSE Healthcare Index Fund0.11%0 -14%
Motilal Oswal BSE 1000 Index Fund0.01%0 -6%

Red flags

F-score 5 of 8
explainShare dilution Share count up 19% in a year, 4667% in three
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Latest quarter

Jun 2026
Sales ₹471 Cr +33.8% vs Jun 2025. Net profit ₹44 Cr +41.9%.
Against our estimate for Jun 2026: sales -6.0%, profit +1.6% in line. Our estimate for Sep 2026: sales Rs 524 Cr, profit Rs 47 Cr (how).

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
No bulk or block deals on record.
Ex-dateActionFactor
2026-01-30Interim Dividend - Rs 2 Per Share
DateTypeWhat it says
2026-10-02Shareholder meetingVoting results.
2026-09-30Shareholder meetingShareholders meeting
2026-09-29Credit Rating- RevisionCredit Rating- Revision
2026-09-15Concall / analyst meetSchedule of meet
2026-09-05General UpdatesGeneral Updates
2026-09-04Shareholder meetingNotice of Annual General Meeting to be held on September 30, 2026
2026-09-03Board meeting outcomeOutcome of Board Meeting held on September 03, 2026.
2026-08-22General UpdatesPursuant to regulation 30 (read with part A of schedule III) and other applicable provisions ofSEBI (Listing Obligations and Disclosure Requirements) ...
2026-08-22Capacity additionCapacity addition
2026-08-22Board meeting outcomeInnova Captab Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
2026-08-14Concall / analyst meetTranscript
2026-08-12Concall / analyst meetLink of Recording
2026-08-11Investor PresentationInvestor Presentation
2026-08-11Press ReleaseA press release dated August 11, 2026, titled "Pursuant to regulation 30 of the Securities Exchange Board of India (Listing Obligations and Disclosure...
2026-08-11Board meeting outcomeInnova Captab Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
2026-08-07Concall / analyst meetSchedule of meet
2026-08-06UpdatesBoard Meeting Intimation To consider and approve the revised Audited Standalone Financial Result of the Company for the quarter and financial year end...
2026-06-24General UpdatesPursuant to the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and in continuation of our earl...
2026-06-08Concall / analyst meetSchedule of meet
2026-06-05General UpdatesGeneral Updates
2026-06-04Shareholder meetingNotice of Annual General Meeting to be held on Jun 29, 2026
2026-05-26General UpdatesGeneral Updates
2026-05-26General UpdatesGeneral Updates in respect of reconstitution of audit committee
2026-05-25Board meeting outcome1. Re-appointment of M/s. B S R & Co. LLP, Chartered Accountants, as the statutory auditors of the Company for the second term of five (5) consecutive...
2026-05-25Board meeting outcome1. Re-appointment of Mr. Manoj Kumar Lohariwala as Whole-Time Director of the Company2. Re-appointment of Mr. Vinay Lohariwala as Managing Director of...
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
High low price variation greater than 100perc in previous 6 months

Quick answers

What is the market cap of Innova Captab Ltd?

Innova Captab Ltd (INNOVACAP) has a market capitalisation of Rs 7,274 Cr. at the 2026-10-01 close.

What is the P/E ratio of Innova Captab Ltd?

Innova Captab Ltd trades at a P/E of 47.2 on trailing twelve-month profit, at the 2026-10-01 close.

What were Innova Captab Ltd's latest quarterly results?

In the Jun 2026 quarter, Innova Captab Ltd sales was Rs 471 Cr (+33.8% vs Jun 2025) and net profit was Rs 44 Cr.

What is the 52-week high and low of Innova Captab Ltd?

The 52-week high is Rs 1,353.50 and the 52-week low is Rs 622.00.

Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.AboutMethodologyFAQResearchContactTermsPrivacyDisclaimerUpdated 2026-10-03